Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM

Y. Desai, Milind; Wolski, Kathy; Owens, Anjali; B. Geske, Jeffrey; Saberi, Sara; Wang, Andrew; Sherrid, Mark; C. Cremer, Paul; K. Lakdawala, Neal; Tower-Rader, Albree; Fermin, David; S. Naidu, Srihari; G. Smedira, Nicholas; Schaff, Hartzell; Gong, Zhiqun; Mudarris, Lana; Lampl, Kathy; J. Sehnert, Amy; E. Nissen, Steven; the VALOR-HCM Investigators, for

doi:10.1161/circulationaha.124.072445

Public

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM

Shared by NobleBlocks on May 13, 2025 • 12:00 AM UTC

Authors:

Milind Y. Desai

Kathy Wolski

Anjali Owens

Abstract

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) ...

Discussions